NCT05912244 2026-02-17A Study of IO102/IO103, Nivolumab, and Relatlimab in People With MelanomaMemorial Sloan Kettering Cancer CenterPhase 2 Active not recruiting43 enrolled
NCT06151236 2026-02-17Neoadjuvant Nivolumab and Relatlimab in Merkel Cell CarcinomaMelanoma Institute AustraliaPhase 2 Recruiting20 enrolled